Melphalan Flufenamide Formulation Stabilization with Gamma-Cyclodextrin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Melphalan flufenamide is unstable in aqueous solutions, leading to rapid degradation and necessitating quick preparation and administration, which limits flexibility in storage and handling.
Innovation Solution
Incorporating γ-cyclodextrin or its pharmaceutically acceptable derivatives, such as hydroxypropyl-γ-cyclodextrin, into melphalan flufenamide formulations to enhance stability and solubility in aqueous solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If melphalan flufenamide is formulated in aqueous solutions for intravenous administration, then the drug can be administered to patients, but the drug degrades rapidly (8-10% per hour at room temperature), requiring quick preparation and administration
Solution Approach 1:
The patent introduces cyclodextrin as an intermediary substance that forms a complex with melphalan flufenamide. This complex acts as a protective intermediary that prevents direct contact between the drug and degrading conditions in aqueous solution, thereby stabilizing the drug without changing the fundamental aqueous formulation approach needed for IV administration.
Solution Approach 2:
The patent changes the chemical environment parameters by incorporating cyclodextrin at specific concentrations (1-10% w/v). This parameter change modifies the solution's protective properties, reducing degradation from 8-10% per hour to less than 1% per hour, thereby extending the usable time window for preparation and administration.
2Adaptability or versatility
If melphalan flufenamide is stored in aqueous solutions for extended periods, then more flexibility in administration is achieved, but the drug concentration decreases due to degradation
Solution Approach 1:
Cyclodextrin serves as a protective intermediary that shields melphalan flufenamide from degradation pathways in aqueous solution. The cyclodextrin-drug complex maintains drug integrity during extended storage periods, allowing concentration to remain stable while providing the needed storage flexibility for clinical administration scheduling.
Solution Approach 2:
The cyclodextrin is incorporated into the formulation beforehand to provide a protective cushion against degradation. This pre-established protection allows the solution to be stored and handled with greater flexibility without anticipating loss of drug concentration, as the cyclodextrin continuously protects the drug molecules from degradation throughout the storage period.
3Productivity
If melphalan flufenamide is reconstituted to higher concentrations to reduce preparation volume, then efficiency improves, but stability in aqueous solution deteriorates
Solution Approach 1:
The cyclodextrin acts as a stabilizing intermediary that enables higher reconstitution concentrations without compromising stability. By forming protective complexes at elevated drug concentrations, the cyclodextrin prevents aggregation and degradation that would normally occur at higher concentrations, thus allowing efficient preparation while maintaining solution stability.
Solution Approach 2:
The patent changes the solution composition parameters by adding cyclodextrin at optimized concentrations (1-10% w/v), which allows the system to tolerate higher drug concentrations. This parameter change modifies the solution's capacity to maintain stability, enabling reconstitution to higher concentrations without the usual stability deterioration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion of γ-cyclodextrin significantly reduces degradation rates, allowing for higher reconstitution concentrations, longer storage periods, and increased flexibility in drug preparation and administration protocols, thereby improving safety and efficiency in clinical settings.
Implementation Method 1
Incorporating γ-cyclodextrin or its pharmaceutically acceptable derivatives, such as hydroxypropyl-γ-cyclodextrin, into melphalan flufenamide formulations to enhance stability and solubility in aqueous solutions
Data Source
AI summary
The invention provides a pharmaceutical preparation comprising melphalan flufenamide, or a salt thereof, and γ-cyclodextrin or a pharmaceutically acceptable derivative of γ-cyclodextrin. The invention further provides compositions comprising the pharmaceutical preparation of the invention, and kits and uses of the pharmaceutical preparations of the invention.